Healthcare professional and patient

logo-image

Welcome to
SYMBICORT

A website for Canadian healthcare professionals

SYMBICORT TURBUHALER:

The #1 dispensed
ICS/LABA1

About SYMBICORT® TURBUHALER®

In Canada, SYMBICORT TURBUHALER is indicated for2

The treatment of asthma in patients 12 years and older with reversible obstructive airways disease.

In Canada, SYMBICORT 200 TURBUHALER and SYMBICORT FORTE TURBUHALER are indicated for2

The maintenance treatment of moderate to severe COPD including chronic bronchitis and emphysema in patients with persistent symptoms and a history of exacerbations, where the use of a combination product is considered appropriate.

Learn more about SYMBICORT TURBUHALER and access resources
designed to help you support your patients below.

COPD: chronic obstructive pulmonary disease; CTS: Canadian Thoracic Society; ICS: inhaled corticosteroid; LABA: long-acting beta2-adrenergic agonist.

 

References:

  1. Data on file. AstraZeneca Canada Inc. April 15, 2024.
  2. Symbicort® Turbuhaler® Product Monograph. AstraZeneca Canada Inc. February 8, 2021.